{
  "thread": {
    "uuid": "a4eae6319649f6dd062e0da7f90d7b9723af3716",
    "url": "https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26",
    "site_full": "www.marketbeat.com",
    "site": "marketbeat.com",
    "site_section": "https://www.marketbeat.com/instant-alerts",
    "site_categories": [
      "investing",
      "financial_news",
      "finance",
      "stocks"
    ],
    "section_title": "\r\n\tStock Market Alerts | MarketBeat\r\n",
    "site_title": "MarketBeat: Stock Market News and Research Tools",
    "title": "Cellectis (NASDAQ:CLLS) Stock Passes Below 50 Day Moving Average - Should You Sell?",
    "title_full": "Cellectis (NASDAQ:CLLS) Stock Passes Below 50 Day Moving Average - Should You Sell?",
    "published": "2025-06-26T12:14:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "https://www.marketbeat.com/logos/cellectis-sa-logo-1200x675.jpg",
    "performance_score": 0,
    "domain_rank": 9003,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "a4eae6319649f6dd062e0da7f90d7b9723af3716",
  "url": "https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26",
  "ord_in_thread": 0,
  "author": "MarketBeat",
  "published": "2025-06-26T12:14:00.000+03:00",
  "title": "Cellectis (NASDAQ:CLLS) Stock Passes Below 50 Day Moving Average - Should You Sell?",
  "text": "Cellectis (NASDAQ:CLLS) Stock Passes Below 50 Day Moving Average - Should You Sell? Written by MarketBeat June 26, 2025 Share Link copied to clipboard. Shares of Cellectis S.A. ( NASDAQ:CLLS - Get Free Report ) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.48 and traded as low as $1.40. Cellectis shares last traded at $1.50, with a volume of 42,342 shares. Get Cellectis alerts: Sign Up Analyst Ratings Changes Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal\nA number of research analysts have recently commented on the stock. Barclays dropped their target price on shares of Cellectis from $5.00 to $4.00 and set an \"overweight\" rating for the company in a report on Tuesday, May 13th. Wall Street Zen lowered shares of Cellectis from a \"hold\" rating to a \"sell\" rating in a research report on Thursday, May 22nd.\nRead Our Latest Research Report on CLLS Cellectis Trading Up 2.0%\nThe business's 50 day simple moving average is $1.48 and its two-hundred day simple moving average is $1.49. The stock has a market cap of $83.37 million, a P/E ratio of -1.74 and a beta of 2.92. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.44.\nCellectis ( NASDAQ:CLLS - Get Free Report ) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). The company had revenue of $12.03 million for the quarter, compared to the consensus estimate of $12.71 million. Cellectis had a negative return on equity of 62.55% and a negative net margin of 114.82%. As a group, analysts expect that Cellectis S.A. will post -0.46 EPS for the current year. Institutional Inflows and Outflows\nSeveral institutional investors and hedge funds have recently made changes to their positions in CLLS. Wells Fargo & Company MN increased its stake in shares of Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after buying an additional 12,500 shares during the period. B Group Inc. acquired a new position in shares of Cellectis in the fourth quarter valued at approximately $5,547,000. Millennium Management LLC acquired a new position in shares of Cellectis in the fourth quarter valued at approximately $962,000. OLD Mission Capital LLC acquired a new position in shares of Cellectis in the first quarter valued at approximately $31,000. Finally, Long Focus Capital Management LLC increased its stake in shares of Cellectis by 2.2% in the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after buying an additional 100,000 shares during the period. Institutional investors and hedge funds own 63.90% of the company's stock. Cellectis Company Profile ( Get Free Report )\nCellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. Further Reading\nThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.\nShould You Invest $1,000 in Cellectis Right Now? Before you consider Cellectis, you'll want to hear this.\nMarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.\nWhile Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.\nView The Five Stocks Here\n12 Stocks Corporate Insiders are Abandoning If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.\nGet This Free Report Like this article? Share it with a colleague. Link copied to clipboard.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "negative",
  "categories": [
    "Education"
  ],
  "topics": null,
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [
    "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CLLS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat",
    "https://twitter.com/intent/tweet?text=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20%24CLLS%20%23CLLS%20https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://www.americanconsumernews.net/scripts/standalone/viewcount.ashx?type=h&id=2875522&domain=marketbeat.com&referrer=",
    "https://www.linkedin.com/cws/share?mini=true&url=https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://twitter.com/intent/tweet?text=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://www.american",
    "https://www.facebook.com/sharer/sharer.php?u=https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://linkedin.com/cws/share?mini=true&url=https://marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://twitter.com/intent/tweet?text=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20%24CLLS%20%23CLLS%20https://marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://www.wallstreetzen.com/newsletters/zen-ratings",
    "https://twitter.com/intent/tweet?text=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20%24CLLS%20%23CLLS%20https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26",
    "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26",
    "https://twitter.com/intent/tweet?text=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20https://marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://wallstreetzen.com/newsletters/zen-ratings?ticker=CLLS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat",
    "https://american",
    "https://twitter.com/intent/tweet?text=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26",
    "https://www.linkedin.com/cws/share?mini=true&url=https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26",
    "https://www.facebook.com/sharer/sharer.php",
    "https://americanconsumernews.net/scripts/standalone/viewcount.ashx?type=h&id=2875522&domain=marketbeat.com&referrer=",
    "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Cellectis+(NASDAQ%3aCLLS)+Stock+Passes+Below+50+Day+Moving+Average+++-+Should+You+Sell%3f%20https://marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://www.linkedin.com/cws/share",
    "https://www.facebook.com/sharer/sharer.php?u=https://www.marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26",
    "https://www.americanconsumernews.net/scripts/standalone/viewcount.ashx",
    "https://api.stocktwits.com/widgets/share",
    "https://facebook.com/sharer/sharer.php?u=https://marketbeat.com/instant-alerts/cellectis-nasdaqclls-stock-passes-below-50-day-moving-average-should-you-sell-2025-06-26/",
    "https://twitter.com/intent/tweet"
  ],
  "entities": {
    "persons": [
      {
        "name": "Marke",
        "sentiment": "neutral"
      }
    ],
    "locations": [],
    "organizations": [
      {
        "name": "Wall Street Zen",
        "sentiment": "none",
        "tickers": []
      },
      {
        "name": "Cellectis S.A.",
        "sentiment": "none",
        "tickers": []
      },
      {
        "name": "Barclays",
        "sentiment": "none",
        "tickers": []
      }
    ]
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null
  },
  "rating": null,
  "crawled": "2025-06-26T12:22:44.646+03:00",
  "updated": "2025-06-26T09:23:42.000+00:00"
}